http://www.fpnotebook.com/
Dabigatran
Aka: Dabigatran, Pradaxa
- Mechanism
- Oral Direct Thrombin Inhibitor
- Pharmacokinetics
- Onset: 1 hour post-ingestion
- Half-life: 15 hours
- Renal excretion
- Indications
- Atrial Fibrillation
- Poor INR control on Warfarin
- Barriers to INR monitoring
- Warfarin Drug Interactions
- Deep Vain Thrombosis (not FDA approved)
- (2009) N Engl J Med 361:2342-52
- Precautions
- No antidote for bleeding
- Bleeding typically stops spontaneously within 6-8 hours (but this is too long in exanguination)
- Focused control of bleeding
- Consider hematology consultation
- Dosing
- Creatinine Clearance >30 ml/minute: 150 mg twice daily
- Creatinine Clearance 15-30 ml/minute: 75 mg twice daily
- This dose has not been tested
- Do not use in patients with Creatinine Clearance <15 ml/minute
- Labs
- No routine labs needed (No monitoring of INR needed)
- If bleeding, expect the following results:
- PTT at 1-2 hours: 2x normal
- PTT at 12 hours: 1.5x normal
- Expect INR to be increased as well
- Thrombin Time is most increased
- Efficacy
- Slightly more effective than Warfarin in prevention against thrombotic events in Atrial Fibrillation
- Prevent 5 more strokes per 1000 patients per year than Warfarin
- Appears as effective as Coumadin in Venous Thromboembolism, but not FDA approved for this indication
- Disadvantages
- Cost: $260/month (contrast with Warfarin which is $80/month with monitoring)
- Twice daily dosing
- Dyspepsia is common
- Not as effective as Warfarin in preventing Myocardial Infarction
- Warfarin prevents 2 more Myocardial Infarctions per 1000 patients than Dabigatran
- Safety
- Fewer intracranial bleeding complications than with Warfarin (Coumadin)
- More Gastrointestinal Bleeding complications than with Coumadin
- References
- (2011) Prescr Lett 18(12):67
- (2012) Prescr Lett 19(3):13
- (2009) N Engl J Med 361:1139-51